日本1型糖尿病成年人血糖控制与患者报告结果之间的关联:SAGE研究的亚分析
Rimei Nishimura1, Akira Shimada2, Norio Abiru3,4
1Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Diabetology international
|March 25, 2024
概括
患有1型糖尿病的日本成年人的心理社会福祉和生活质量随着年龄的增长而改善. 更好的血糖控制与对胰岛素治疗的更高满意度有关.
科学领域:
- 内分泌学 在内分泌学.
- 心理学 心理学 心理学
- 公共卫生 公共卫生
背景情况:
- 心理社会因素和生活质量 (QOL) 对于管理糖尿病和实现治疗目标至关重要.
- 患者报告结果 (PROs) 提供了对糖尿病患者生活经验的宝贵见解.
研究的目的:
- 描述1型糖尿病 (T1D) 的日本成年人的PRO.
- 评估不同年龄段的PRO和血糖控制之间的关联.
主要方法:
- 在SAGE研究中对528名日本T1D参与者进行了亚分析.
- 数据包括各年龄段 (26-44,45-64,≥65岁) 的糖化血红蛋白 (HbA1c) 和PRO得分 (HFS-II,PAID,ITSQ,ADDQoL).
- 多变量逻辑回归分析了PROs,HbA1c目标和治疗满意度之间的关联.
主要成果:
- 老年人 (≥65岁) 报告说,与年轻人相比,他们对低血糖症 (HFS-II) 和糖尿病困扰 (PAID) 的恐惧较低,对治疗的满意度更高 (ITSQ).
- 一个线性趋势表明,随着年龄的增长,得分有所改善 (P < 0.05).
- 生活质量 (ADDQoL) 在各个年龄组中是相似的,目前的QOL往往随着年龄的增长而改善 (P < 0.05).
- 达到HbA1c<7.0%和与胰岛素治疗对血糖控制的满意度相关的个性化目标.
结论:
- 在患有T1D的日本成年人中,心理社会方面和QOL因年龄而异,老年人有改善的趋势.
- 这可能与老年人群中不那么严格的血糖控制目标有关.
- 血糖控制与治疗满意度有显著的关联.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications
530
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
530
Diabetes: Management and Pharmacotherapy
277
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
277
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Insulin: Dosing Regimen and Adverse Effects
169
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
169


